Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank

Condition(s) studied

Investigational drug(s) / intervention(s)

patient registry (observation and biomaterial sampling): data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected

Study summary

Born out of the European Union 7th Framework Programme funded project European IPF Network (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of longitudinal data from IPF patients, including control groups of patients with other lung diseases. The registry was initiated with the intention of creating a permanent and continuously growing record of well defined data on IPF in Europe, in order to increase the chances of finding better treatment options for this devastating disease.

Clinical colleagues who would like to actively participate (both in terms of patient recruitment and data analysis) are invited to contact us (http://www.pulmonary-fibrosis.net/).

Eligibility

Primary outcome measure(s)

• clinical course of patients with Interstitial Lung Diseases (ILD) — 5 years
  change of lung function parameter such as forced vital capacity (FVC), diffusing lung capacity (DLCO) over time mortality symptoms (reported in patients questionnaires)

Trial sites (7)

Other trials for the same condition